| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
239,094 |
214,946 |
$13.85M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
178,107 |
157,112 |
$8.09M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
80,800 |
73,676 |
$5.45M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
98,706 |
90,242 |
$5.00M |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
123,319 |
109,750 |
$3.72M |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
8,008 |
7,360 |
$1.54M |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
105,691 |
45,554 |
$1.01M |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
75,241 |
67,448 |
$768K |
| 99051 |
|
129,907 |
117,271 |
$533K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
6,833 |
6,235 |
$277K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
6,862 |
6,182 |
$256K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
21,177 |
16,849 |
$229K |
| 99215 |
Prolong outpt/office vis |
2,853 |
2,682 |
$220K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
9,822 |
9,116 |
$214K |
| 99205 |
Prolong outpt/office vis |
1,181 |
1,111 |
$99K |
| 87481 |
|
2,873 |
2,613 |
$99K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
5,076 |
4,664 |
$97K |
| 87653 |
|
4,152 |
3,865 |
$94K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
3,762 |
3,553 |
$87K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
3,769 |
3,557 |
$85K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
3,692 |
3,493 |
$74K |
| 87529 |
|
1,598 |
1,542 |
$73K |
| 87511 |
|
2,862 |
2,705 |
$60K |
| 81002 |
|
16,782 |
15,278 |
$40K |
| 87641 |
|
1,622 |
1,521 |
$37K |
| 81025 |
|
3,325 |
3,159 |
$19K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,755 |
1,544 |
$16K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
154 |
150 |
$15K |
| 87480 |
|
973 |
943 |
$12K |
| 99201 |
|
264 |
257 |
$12K |
| 81003 |
|
7,010 |
6,538 |
$11K |
| 87498 |
|
458 |
406 |
$9K |
| 86580 |
|
849 |
606 |
$7K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
7,520 |
6,630 |
$7K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
98 |
97 |
$6K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
3,319 |
2,936 |
$6K |
| 90714 |
|
156 |
144 |
$3K |
| 36415 |
Collection of venous blood by venipuncture |
1,058 |
967 |
$3K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,920 |
1,712 |
$3K |
| 69209 |
|
396 |
335 |
$3K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
105 |
85 |
$3K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
120 |
98 |
$2K |
| 10060 |
|
36 |
36 |
$2K |
| 99384 |
|
31 |
31 |
$2K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
137 |
122 |
$2K |
| 87428 |
|
44 |
41 |
$1K |
| 87640 |
|
66 |
53 |
$1K |
| 12001 |
|
13 |
13 |
$808.20 |
| 87500 |
|
32 |
32 |
$803.28 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
40 |
34 |
$736.77 |
| 71046 |
Radiologic examination, chest; 2 views |
62 |
55 |
$687.90 |
| 93000 |
|
52 |
52 |
$685.55 |
| 73610 |
|
29 |
29 |
$665.32 |
| 86328 |
|
37 |
35 |
$603.32 |
| 69210 |
|
32 |
27 |
$587.74 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
139 |
130 |
$519.90 |
| 87088 |
|
140 |
130 |
$515.54 |
| 86308 |
|
145 |
144 |
$494.03 |
| 73630 |
|
27 |
27 |
$446.16 |
| 87581 |
|
13 |
13 |
$342.16 |
| 87486 |
|
16 |
13 |
$334.54 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
246 |
214 |
$323.46 |
| 87541 |
|
15 |
12 |
$308.22 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
836 |
763 |
$259.08 |
| 86696 |
|
32 |
27 |
$217.67 |
| 82962 |
|
70 |
67 |
$210.22 |
| 73130 |
|
12 |
12 |
$202.80 |
| 69200 |
|
13 |
13 |
$196.89 |
| A6449 |
Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard |
204 |
200 |
$180.60 |
| 86803 |
|
16 |
15 |
$145.33 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
234 |
221 |
$83.63 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
16 |
13 |
$74.53 |
| A6450 |
Light compression bandage, elastic, knitted/woven, width greater than or equal to five inches, per yard |
58 |
56 |
$49.36 |
| A4565 |
Slings |
12 |
12 |
$45.00 |
| 86695 |
|
30 |
26 |
$39.56 |
| S9083 |
Global fee urgent care centers |
209 |
163 |
$37.20 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
35 |
30 |
$36.12 |
| 86592 |
|
17 |
14 |
$22.40 |
| 80305 |
|
55 |
29 |
$20.20 |
| 76140 |
|
19 |
17 |
$0.00 |
| 99173 |
|
47 |
39 |
$0.00 |
| 99000 |
|
451 |
417 |
$0.00 |